BBH - ETF AI Analysis
Top Page
VanEck Biotech ETF (BBH)
Rating:71Outperform
Price Target:―
Positive Factors
Established Large-Cap Biotech Leaders
Top holdings like Amgen and Gilead Sciences have shown solid gains this year, helping support the fund’s overall results.
Targeted Biotech Exposure
The ETF focuses almost entirely on health care and biotech companies, giving investors a concentrated way to benefit if the biotech sector does well.
Moderate Expense Ratio
The fund’s fee is reasonable for a specialized biotech ETF, allowing investors to keep more of any potential returns.
Negative Factors
High Stock Concentration
A small number of companies make up a large share of the portfolio, which increases the impact if any of these big positions perform poorly.
Many Weak Recent Performers
Several of the top holdings have shown weak performance so far this year, which can drag on the ETF’s overall returns.
Narrow Sector and U.S. Focus
Almost all assets are in U.S. health care and biotech stocks, offering little diversification across sectors or regions.
BBH vs. SPDR S&P 500 ETF (SPY)
AUM398.53M
RegionGlobal
Expense Ratio0.35%
Beta0.60
IssuerVanEck
Inception DateDec 20, 2011
Dividend Yield0.47%
Asset ClassEquity
Index TrackedMVIS US Listed Biotech 25
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,882
30 Day Avg. Volume4,989
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
232.99Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering24
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBH Summary
The VanEck Biotech ETF (BBH) is a fund that follows the MVIS US Listed Biotech 25 Index and focuses on biotechnology companies within the health care sector. It holds well-known names like Amgen and Gilead Sciences, along with other firms working on new drugs, genetic research, and advanced medical treatments. Someone might invest in BBH to seek long-term growth from medical breakthroughs and to get broad exposure to leading biotech companies in a single investment. However, biotech stocks can be very volatile, so the ETF’s price can rise and fall sharply based on drug trial results, regulations, and overall market conditions.
How much will it cost me?The VanEck Biotech ETF (BBH) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused ETF that targets biotechnology companies, which often require more active management to track this specialized market. It’s important to consider whether the potential growth in this niche sector aligns with your investment goals.
What would affect this ETF?The VanEck Biotech ETF (BBH) could benefit from advancements in biotechnology, such as breakthroughs in drug development and genetic research, as well as increased global demand for innovative health solutions. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding for biotech companies. Additionally, changes in interest rates could affect the financial performance of its top holdings like Gilead Sciences and Amgen.
BBH Top 10 Holdings
BBH is a pure biotech play, and its story is being written by a handful of heavyweight drug makers and fast-moving innovators. Amgen and Vertex have been relatively steady to rising, helping to anchor returns, while Biogen’s recent upswing adds a bit of extra lift. On the flip side, Regeneron and Alnylam have been lagging, acting like a brake on the portfolio, and IQVIA’s slump isn’t helping. With all holdings tied to health care and mostly U.S.-listed names, this is a concentrated bet on biotech breakthroughs rather than broad global diversification.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Amgen | 15.30% | $61.01M | $197.69B | 23.08% | 77 Outperform | |
| Gilead Sciences | 13.48% | $53.76M | $166.72B | 23.02% | 78 Outperform | |
| Vertex Pharmaceuticals | 8.83% | $35.20M | $123.26B | 4.80% | 78 Outperform | |
| Regeneron | 6.69% | $26.65M | $70.94B | 23.21% | 78 Outperform | |
| Revolution Medicines | 5.20% | $20.73M | $39.58B | 369.52% | 52 Neutral | |
| Natera | 4.88% | $19.45M | $38.87B | 86.75% | 73 Outperform | |
| Argenx Se | 4.58% | $18.24M | $53.70B | 49.47% | 79 Outperform | |
| IQVIA Holdings | 4.56% | $18.18M | $34.42B | 28.27% | 73 Outperform | |
| Biogen | 3.43% | $13.68M | $30.41B | 62.98% | 74 Outperform | |
| Alnylam Pharma | 3.38% | $13.47M | $35.71B | -14.93% | 60 Neutral |
BBH Technical Analysis
Neutral
―
Price Trends
192.79
Positive
190.62
Positive
189.44
Positive
Market Momentum
3.59
Positive
53.36
Neutral
20.62
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 203.39, equal to the 50-day MA of 192.79, and equal to the 200-day MA of 189.44, indicating a neutral trend. The MACD of 3.59 indicates Positive momentum. The RSI at 53.36 is Neutral, neither overbought nor oversold. The STOCH value of 20.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BBH.
BBH Peer Comparison
Comparison Results
Performance Comparison
BBH
VanEck Biotech ETF
203.42
43.63
27.30%
TRFK
Pacer Data and Digital Revolution ETF
―
―
―
PPH
VanEck Pharmaceutical ETF
―
―
―
GII
SPDR S&P Global Infrastructure ETF
―
―
―
AVRE
Avantis Real Estate ETF
―
―
―
CANC
Tema Oncology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents